Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HSD17B10



This biomarker is also known as:
  • 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
  • MRXS10,
  • XH98G2,
  • short chain type dehydrogenase/reductase XH98G2,
  • SDR5C1,
  • Mitochondrial RNase P protein 2,
  • MHBD,
  • mental retardation, X-linked, syndromic 10,
  • DUPXp11.22,
  • mitochondrial ribonuclease P protein 2,
  • 3-hydroxyacyl-CoA dehydrogenase type II,
  • CAMR,
  • hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
  • 17-beta-HSD 10,
  • EC,EC,
  • 17-beta-hydroxysteroid dehydrogenase 10,
  • Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
  • hydroxysteroid (17-beta) dehydrogenase 10,
  • SCHAD,
  • MRX17,
  • MRX31,
  • Short-chain type dehydrogenase/reductase XH98G2,
  • Mitochondrial ribonuclease P protein 2,
  • Type II HADH,
  • ERAB,
  • mitochondrial RNase P subunit 2,
  • AB-binding alcohol dehydrogenase,
  • MRPP2,
  • endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
  • 3-hydroxyacyl-CoA dehydrogenase type-2,
  • amyloid-beta peptide binding alcohol dehydrogenase,
  • ABAD,
  • HCD2,
  • HADH2,
  • short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
  • short chain dehydrogenase/reductase family 5C, member 1,
  • 17b-HSD10,

View in BioMuta


HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: HSD17B10


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data is available.

Performance Comment

HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.